ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2018
Helping Patients With ESRD and Earlier Stages of CKD to Quit Smoking.
Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Practical recommendations for treating patients with chronic kidney disease in Australia: a multidisciplinary approach.Internal medicine journal · 2026Article
- Smoking as a causative factor in chronic kidney disease: a two-sample Mendelian randomization study.Renal failure · 2025Article
- The Exposome and the Kidney: A Silent Dialogue Shaping Chronic Kidney Disease.Journal of xenobiotics · 2025Review
- Renal function and efficacy of dual antiplatelet vs. alteplase in minor stroke: aFrontiers in neurology · 2025Article
- Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies.Clinics in liver disease · 2024Review
- Sex disparities in the association between serum cotinine and chronic kidney disease.Tobacco induced diseases · 2024Article
- Preexisting Cardiovascular Disease, Hypertension, and Mortality in Peritoneal Dialysis.Reviews in cardiovascular medicine · 2023Article
- Effect of Uncertainty in Illness and Fatigue on Health-Related Quality of Life of Patients on Dialysis: A Cross-Sectional Correlation Study.Healthcare (Basel, Switzerland) · 2022Article
- Nursing Countermeasures of Continuous Renal Replacement Treatment in End-Stage Renal Disease with Refractory Hypotension in the Context of Smart Health.Computational and mathematical methods in medicine · 2022Article
- Factors associated with quitting status of smoking in Korean men with and without chronic kidney disease: A national population-based study.Tobacco induced diseases · 2022Article
- How to manage cigarette smoking in kidney transplant candidates and recipients?Clinical kidney journal · 2021Article
- Nicotine exacerbates tacrolimus-induced renal injury by programmed cell death.The Korean journal of internal medicine · 2021Article
- Child-to-adult body mass index trajectories and the risk of subclinical renal damage in middle age.International journal of obesity (2005) · 2021Article
- Association of Blood Pressure Trajectories in Early Life with Subclinical Renal Damage in Middle Age.Journal of the American Society of Nephrology : JASN · 2018Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Among the many adverse effects of tobacco exposure is the increased risk for progression of kidney disease. Individuals with chronic kidney disease (CKD), who already face increased cardiovascular event rates compared to the general population, are at even greater risk if they smoke. Despite these risks and the increased focus on smoking cessation in the general population in recent years, national guidelines have not specifically targeted individuals with CKD. There are similarly sparse data specific to individuals with CKD regarding the safety and efficacy of evidence-based smoking cessation modalities. This review aims to identify the risks of nicotine dependence in individuals with CKD and the potential benefits of smoking cessation; discuss current strategies for smoking cessation, including behavioral and pharmacologic therapies such as varenicline; and extrapolate these interventions to the unique challenges of this population. Much of the data presented stem from evidence for the general population but are described with additional consideration in dosing of nicotine replacement therapy, as well as non-nicotine pharmacotherapy and treatment modality for individuals with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.